Semantic Obfuscation in Hormone Therapy and Its Consequences

This article strives to expose and clarify persistent linguistic ambiguities in menopausal hormone replacement therapy. With the development of precise language and an integrated understanding of the essential systemic regulatory functions of estrogen and progesterone, clinicians and patients can engage in the common goal of optimized, precision medicine. The widespread underrecognition of estrogen and progesterone as essential systemic hormones is not due to lack of evidence—it stems from longstanding structural, educational, and linguistic failures in medicine. Historically, women were excluded from biomedical research, and female-specific hormones were categorized narrowly as reproductive modulators. This androcentric framework ignored their broader roles in brain, bone, immune, and cardiovascular health. The fallout from the Women's Health Initiative (WHI) amplified confusion by attributing risks observed with synthetic progestins (e.g., MPA) to all hormone therapies. Terminological ambiguity—using “estrogen” and “progesterone” interchangeably for synthetic analogsfurther distorted clinical perception. Despite evidence that bioidentical, transdermal hormones behave differently, medical training and regulatory guidance have not adapted. Moreover, no specialty has assumed full responsibility for systemic hormone replacement. Gynecology focuses on symptoms, endocrinology ignores menopause, and primary care lacks infrastructure to manage nuance. Compounding this, menopause is framed as a natural, inevitable life stage rather than a modifiable endocrine collapse—leading to untreated bone loss, cognitive decline, and immune dysfunction. Until medicine reframes estrogen and progesterone as central to systemic health—on par with thyroid and adrenal hormones—patients will continue to be misinformed, mismanaged, and underserved. The language used in menopausal hormone therapy (MHT) has long been a source of clinical confusion, regulatory ambiguity, and public misunderstanding. Terms like "progesterone," "progestin," "hormone replacement therapy (HRT)," and branded drug names such as "PremPro" have obscured critical distinctions in pharmacology, safety, and therapeutic rationale. This semantic ambiguity has distorted risk communication, impaired informed consent, and undermined the integration of bioidentical hormones into mainstream care.